References
- Cabibbo G, Maida M, Genco C, et al. Causes of and prevention strategies for hepatocellular carcinoma. Semin Oncol 2012;39:374-83
- Cammà C, Cabibbo G. Prognostic scores for hepatocellular carcinoma: none is the winner. Liver Int 2009;29:478-80
- Maida M, Orlando E, Cammà C, Cabibbo G. Staging systems of hepatocellular carcinoma: a review of literature. World J Gastroenterol 2014;20:4141-50
- Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology 2010;52:762-73
- Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35(3):421-30
- European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908-43
- Sacco R, Gadaleta-Caldarola G, Galati G, et al. European Association for the Study of the Liver Hepatocellular Carcinoma summit 2014: old questions, new (or few) answers? Future Oncol 2014;10(10):1719-21
- Maida M, Cabibbo G, Brancatelli G, et al. Assessment of treatment response in hepatocellular carcinoma: a review of the literature. Future Oncol 2013;9:845-54
- Cabibbo G, Maida M, Genco C, et al. Survival of patients with hepatocellular carcinoma (HCC) treated by percutaneous radio-frequency ablation (RFA) is affected by complete radiological response. PLoS One 2013;8:e70016
- Orlando A, Leandro G, Olivo M, et al. Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials. Am J Gastroenterol 2009;104:514-24
- Cho YK, Kim JK, Kim MY, et al. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology 2009;49:453-9
- Germani G, Pleguezuelo M, Gurusamy K, et al. Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta-analysis. J Hepatol 2010;52:380-8
- Giorgio A, Di Sarno A, De Stefano G, et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma compared to percutaneous ethanol injection in treatment of cirrhotic patients: an Italian randomized controlled trial. Anticancer Res 2011;31:2291-5
- Oeda S, Mizuta T, Isoda H, et al. Survival advantage of radiofrequency ablation for hepatocellular carcinoma: comparison with ethanol injection. Hepatogastroenterology 2013;60:1399-404
- Shen A, Zhang H, Tang C, et al. Systematic review of radiofrequency ablation versus percutaneous ethanol injection for small hepatocellular carcinoma up to 3 cm. J Gastroenterol Hepatol 2013;28:793-800
- Forner A, Bruix J. Ablation for hepatocellular carcinoma: is there need to have a winning technique? J Hepatol 2010;52:310-12
- Cucchetti A, Piscaglia F, Cescon M, et al. Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma. J Hepatol 2013;59:300-7
- Pompili M, Mirante VG, Rondinara G, et al. Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: assessment of efficacy at explant analysis and of safety for tumor recurrence. Liver Transpl 2005;11:1117-26
- Branco F, Brú C, Vilana R, et al. Percutaneous ethanol injection before liver transplantation in the hepatocellular carcinoma. Ann Hepatol 2009;8:220-7
- Eguchi S, Hidaka M, Tomonaga T, et al. Actual therapeutic efficacy of pre-transplant treatment on hepatocellular carcinoma and its impact on survival after salvage living donor liver transplantation. J Gastroenterol 2009;44:624-9
- Peng ZW, Zhang YJ, Chen MS, et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol 2013;31:426-32
- Genco C, Cabibbo G, Maida M, et al. Treatment of hepatocellular carcinoma: present and future. Expert Rev Anticancer Ther 2013;13(4):469-79
- Bruix J, Tatayama T, Mazzaferro V, et al. STORM: a phase III randomized, double-blind, placebo-controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma (HCC). J Clin Oncol 2004;32(5s Suppl)):abstract 4006